09/700,462

```
FILE 'HOME' ENTERED AT 16:50:23 ON 18 OCT 2002

=> file biosis medline caplus wpids uspatfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'BIOSIS' ENTERED AT 16:51:02 ON 18 OCT 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 16:51:02 ON 18 OCT 2002

FILE 'CAPLUS' ENTERED AT 16:51:02 ON 18 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 16:51:02 ON 18 OCT 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'USPATFULL' ENTERED AT 16:51:02 ON 18 OCT 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s mass spectromet?
L1      308916 MASS SPECTROMET?

=> s l1 and mass tag?
L2          156 L1 AND MASS TAG?

=> s l2 and librar?
L3           40 L2 AND LIBRAR?

=> s l3 and monomethoxytrityl?
L4            2 L3 AND MONOMETHOXYTRITYL?

=> d l4 bib abs 1-2

L4   ANSWER 1 OF 2  USPATFULL
AN     2002:63679  USPATFULL
TI     Compositions and methods for enhancing hybridization and priming
       specificity
IN     Van Ness, Jeffrey, Seattle, WA, United States
       Tabone, John C., Bothell, WA, United States
       Garrison, Lori K., Seattle, WA, United States
PA     QIAGEN Genomics, Inc., Bothell, WA, United States (U.S. corporation)
PI     US 6361940          B1   20020326
AI     US 1998-53831            19980401 (9)
RLI    Continuation-in-part of Ser. No. US 1997-2051, filed on 31 Dec 1997, now
       abandoned Continuation-in-part of Ser. No. US 1997-933924, filed on 23
       Sep 1997, now abandoned
PRAI   US 1996-26621P      19960924 (60)
DT     Utility
FS     GRANTED
EXNAM  Primary Examiner: Riley, Jezia
LREP   Seed Intellectual Property Law Group PLLC
CLMN   Number of Claims: 97
ECL    Exemplary Claim: 1
DRWN   33 Drawing Figure(s); 30 Drawing Page(s)
LN.CNT 6301
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

AB Compositions and methods are provided for increasing the specificity of a probe nucleic acid for a target nucleic acid in a hybridization solution. An abasic residue, deoxyNebularine residue, or a hybotrope is used to increase specificity. A method is provided for identifying useful hybotropes, including salts, water miscible organic solvents, aprotic solvents and organic solvents, on the basis of enthalpy considerations. Hybotropic hybridization and modified oligonucleotides may be used in amplification reactions, such as PCR, sequence analysis methods, and genomic screening methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 2 USPATFULL
AN 2002:43173 USPATFULL
TI Methods for preparing conjugates
IN Dellinger, Douglas J., Sunnyvale, CA, UNITED STATES
Myerson, Joel, Berkeley, CA, UNITED STATES
Fulcrand, Geraldine, Sunnyvale, CA, UNITED STATES
Ilsley, Diane D., San Jose, CA, UNITED STATES
PI US 2002025539 A1 20020228
AI US 2001-981580 A1 20011017 (9)
RLI Division of Ser. No. US 1999-397526, filed on 16 Sep 1999, PENDING
DT Utility
FS APPLICATION
LREP AGILENT TECHNOLOGIES, INC., Legal Department, DL429, Intellectual Property Administration, P. O. Box 7599, Loveland, CO, 80537-0599
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1750
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are disclosed for conjugating one moiety to another moiety. In the method the moieties are reacted with one another in a protic solvent. Reaction between the moieties and the protic solvent during the conjugating is negligible or reversible. A stable bond is formed between the moieties to produce a product that is not subject to .beta.-elimination at elevated pH. Usually, one of the moieties comprises an unsaturation between two carbon atoms. One of the carbon atoms is or becomes an electrophile during the conjugating. The other of the moieties comprises a functionality reactive with the electrophile carbon atom to form a product that comprises the unsaturation. Compounds comprising both of the moieties as well as precursor molecules are also disclosed. Methods are also disclosed for determining an analyte in a sample employing compounds as described above.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> s l1 and monomethoxytrityl?
L6          80 L1 AND MONOMETHOXYTRITYL?

=> s l6 and tag
L7          23 L6 AND TAG

=> s l7 not l4
L8          21 L7 NOT L4

=> dup rem l8
PROCESSING COMPLETED FOR L8
L9           21 DUP REM L8 (0 DUPLICATES REMOVED)

=> d l9 bib abs 1-21

L9   ANSWER 1 OF 21  USPATFULL
AN     2002:272783  USPATFULL
TI     Polynucleotide sequence assay
IN     Bi, Wanli, San Ramon, CA, UNITED STATES
       Livak, Kenneth J., San Jose, CA, UNITED STATES
       Bloch, Will, White Salmon, WA, UNITED STATES
PI     US 2002150904      A1   20021017
AI     US 2001-898323     A1   20010703 (9)
PRAI   US 2000-216514P     20000703 (60)
DT     Utility
FS     APPLICATION
LREP   PATTI SELAN, PATENT ADMINISTRATOR, APPLIED BIOSYSTEMS, 850 LINCOLN
       CENTRE DRIVE, FOSTER CITY, CA, 94404
CLMN   Number of Claims: 158
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 2135
AB     Disclosed are methods for detecting or quantifying one or more target
       polynucleotide sequences in a sample. In one aspect, a sample is
       contacted with first and second probe pair that are capable of
       hybridizing to a selected target sequence and a corresponding
       complementary sequence, respectively. Probe cleavage and ligation
       results in the formation of ligation products which can be generated in
       an exponential fashion when the target sequence and/or complement are
       present in the sample. In another embodiment, a single probe pair can be
       used to form ligation product in a linear fashion from a complementary
       template. Reagents and kits are also disclosed.


L9   ANSWER 2 OF 21  USPATFULL
AN     2002:221317  USPATFULL
TI     Methods and compositions for determining the sequence of nucleic acid
       molecules
IN     Ness, Jeffrey Van, Seattle, WA, UNITED STATES
       Tabone, John C., Bothell, WA, UNITED STATES
       Howbert, J. Jeffry, Bellevue, WA, UNITED STATES
       Mulligan, John T., Seattle, WA, UNITED STATES
PI     US 2002119456      A1   20020829
AI     US 2001-855999     A1   20010514 (9)
RLI    Continuation of Ser. No. US 1997-898180, filed on 22 Jul 1997, PATENTED
       Continuation-in-part of Ser. No. US 1997-786835, filed on 22 Jan 1997,
       ABANDONED
PRAI   US 1996-10462P      19960123 (60)
DT     Utility
FS     APPLICATION
LREP   SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
       SEATTLE, WA, 98104-7092
CLMN   Number of Claims: 58
```

ECL Exemplary Claim: 1
DRWN 25 Drawing Page(s)
LN.CNT 6401
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compounds, including compositions therefrom, are provided for determining the sequence of nucleic acid molecules. The methods permit the determination of multiple nucleic acid sequences simultaneously. The compounds are used as tags to generate tagged nucleic acid fragments which are complementary to a selected target nucleic acid molecule. Each **tag** is correlative with a particular nucleotide and, in a preferred embodiment, is detectable by **mass spectrometry**. Following separation of the tagged fragments by sequential length, the tags are cleaved from the tagged fragments. In a preferred embodiment, the tags are detected by **mass spectrometry** and the sequence of the nucleic acid molecule is determined therefrom. The individual steps of the methods can be used in automated format, e.g., by the incorporation into systems.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 21 USPATFULL
AN 2002:108823 USPATFULL
TI **Mass spectrometric** detection of polypeptides
IN Little, Daniel, Boston, MA, United States
Koster, Hubert, La Jolla, CA, United States
Higgins, G. Scott, Paisley, UNITED KINGDOM
Lough, David, Berwickshire, UNITED KINGDOM
PA Sequenom, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6387628 B1 20020514
AI US 2000-664977 20000918 (9)
RLI Division of Ser. No. US 1998-146054, filed on 2 Sep 1998
Continuation-in-part of Ser. No. US 1997-922201, filed on 2 Sep 1997
DT Utility
FS GRANTED
EXNAM Primary Examiner: Campbell, Eggerton A.
LREP Heller Ehrman White & McAuliffe
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 4716
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for determining the identity of a target polypeptide using mass spectroscopy is provided. Depending on the target polypeptide to be identified, a process as disclosed can be used, for example, to diagnose a genetic disease or chromosomal abnormality, a predisposition to a disease or condition, or infection by a pathogenic organism; or for determining identity or heredity. Kits for performing the disclosed processes also are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 21 USPATFULL
AN 2002:1324 USPATFULL
TI Methods for the preparation of conjugated oligomers
IN Manoharan, Muthiah, Carlsbad, CA, United States
PA ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)
PI US 6335437 B1 20020101
AI US 1998-149156 19980907 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Wilson, James O.; Assistant Examiner: Owens, Howard
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP

CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1645
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel methods for preparing oligonucleotide conjugates using a novel electrophilic haloacetyl linker. Novel compounds and intermediates are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 21 USPATFULL
AN 2001:214828 USPATFULL
TI **Mass spectrometric** detection of polypeptides
IN Little, Daniel, Boston, MA, United States
Koster, Hubert, La Jolla, CA, United States
Higgins, G. Scott, Paisley, United Kingdom
Lough, David, Berwickshire, United Kingdom
PA Sequenom, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6322970 B1 20011127
AI US 1998-146054 19980902 (9)
RLI Continuation-in-part of Ser. No. US 1997-922201, filed on 2 Sep 1997
DT Utility
FS GRANTED
EXNAM Primary Examiner: Campbell, Eggerton A.
LREP Seidman, Stephanie L.Heller Ehrman White & McAuliffe LLP
CLMN Number of Claims: 95
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 4786
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for determining the identity of a target polypeptide using mass spectroscopy is provided. Depending on the target polypeptide to be identified, a process as disclosed can be used, for example, to diagnose a genetic disease or chromosomal abnormality, a predisposition to a disease or condition, or infection by a pathogenic organism; or for determining identity or heredity. Kits for performing the disclosed processes also are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 21 USPATFULL
AN 2001:202419 USPATFULL
TI Polymerase extension at 3' terminus of PNA-DNA chimera
IN Egholm, Michael, Wayland, MA, United States
Chen, Caifu, Brookline, MA, United States
PA Applera Corporation, Foster City, CA, United States (U.S. corporation)
PI US 6316230 B1 20011113
AI US 1999-373845 19990813 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Riley, Jezia
LREP Andrus, Alex
CLMN Number of Claims: 43
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 17 Drawing Page(s)
LN.CNT 1634
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods and a kit for primer extension of PNA-DNA chimera from template nucleic acids using polymerases, nucleotide 5'-triphosphates, and primer extension reagents. Structural requirements of the chimera for primer extension include 5 to 15 contiguous PNA monomer units, 3 or more contiguous nucleotides, and a 3' hydroxyl terminus. The chimera and/or a nucleotide is labelled with fluorescent

dyes or other labels. The methods include DNA sequencing, DNA fragment analysis, reverse transcription, mini-sequencing, chromosome labelling, amplification, and single nucleotide polymorphism (SNP) detection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 21 USPATFULL
AN 2001:196797 USPATFULL
TI Methods and compositions for determining the sequence of nucleic acid molecules
IN Van Ness, Jeffrey, Seattle, WA, United States
Tabone, John C., Bothell, WA, United States
Howbert, J. Jeffry, Bellevue, WA, United States
Mulligan, John T., Seattle, WA, United States
PA Qiagen Genomics, Inc., Bothell, WA, United States (U.S. corporation)
PI US 6312893 B1 20011106
AI US 1997-898180 19970722 (8)
RLI Continuation-in-part of Ser. No. US 1997-786835, filed on 22 Jan 1997, now abandoned
PRAI US 1996-10462P 19960123 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Houtteman, Scott W.
LREP Seed Intellectual Property Law Group PLLC
CLMN Number of Claims: 58
ECL Exemplary Claim: 1
DRWN 46 Drawing Figure(s); 42 Drawing Page(s)
LN.CNT 6431
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compounds, including compositions therefrom, are provided for determining the sequence of nucleic acid molecules. The methods permit the determination of multiple nucleic acid sequences simultaneously. The compounds are used as tags to generate tagged nucleic acid fragments which are complementary to a selected target nucleic acid molecule. Each **tag** is correlative with a particular nucleotide and, in a preferred embodiment, is detectable by **mass spectrometry**. Following separation of the tagged fragments by sequential length, the tags are cleaved from the tagged fragments. In a preferred embodiment, the tags are detected by **mass spectrometry** and the sequence of the nucleic acid molecule is determined therefrom. The individual steps of the methods can be used in automated format, e.g., by the incorporation into systems.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 21 USPATFULL
AN 2001:29748 USPATFULL
TI Aminooxy-modified oligonucleotide synthetic intermediates
IN Cook, Phillip Dan, Lake San Marcos, CA, United States
Manoharan, Muthiah, Carlsbad, CA, United States
Kawasaki, Andrew Mamoru, Oceanside, CA, United States
PA ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)
PI US 6194598 B1 20010227
AI US 2000-477902 20000105 (9)
RLI Division of Ser. No. US 1998-16520, filed on 30 Jan 1998
PRAI US 1997-37143P 19970214 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Gitomer, Ralph; Assistant Examiner: Crane, L. E.
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP
CLMN Number of Claims: 6
ECL Exemplary Claim: 1

DRWN 29 Drawing Figure(s); 29 Drawing Page(s)
LN.CNT 3095
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nucleotide compositions containing aminooxy moieties are provided. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the nucleoside moieties of the oligonucleotide is modified to include an aminooxy moiety.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 21 USPATFULL
AN 2001:4883 USPATFULL
TI Aminooxy-modified oligonucleotides and methods for making same
IN Manoharan, Muthiah, Carlsbad, CA, United States
Cook, Phillip Dan, Lake San Marcos, CA, United States
Prakash, Thazha P., Carlsbad, CA, United States
Kawasaki, Andrew M., Oceanside, CA, United States
PA ISIS Pharmaceuticals Inc., Carlsbad, CA, United States (U.S. corporation)
PI US 6172209 B1 20010109
AI US 1998-130973 19980807 (9)
RLI Continuation-in-part of Ser. No. US 1998-16520, filed on 30 Jan 1998
PRAI US 1997-37143P 19970214 (60)
DT Patent
FS Granted
EXNAM Primary Examiner: Geist, Gary; Assistant Examiner: Crane, Larson
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 29 Drawing Figure(s); 29 Drawing Page(s)
LN.CNT 3602
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Oligonucleotides and other macromolecules are provided which have increased nuclease resistance, substituent groups (such as 2'-aminooxy groups) for increasing binding affinity to complementary strand, and subsequences of 2'-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H. Such oligonucleotides and macromolecules are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 21 USPATFULL
AN 2000:146099 USPATFULL
TI DNA sequencing by **mass spectrometry** via exonuclease degradation
IN Koster, Hubert, Concord, MA, United States
PA Sequenom, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6140053 20001031
AI US 1998-160671 19980925 (9)
RLI Continuation of Ser. No. US 1996-744590, filed on 6 Nov 1996 which is a continuation-in-part of Ser. No. US 1995-388171, filed on 10 Feb 1995, now patented, Pat. No. US 5622824 which is a continuation of Ser. No. US 1993-34738, filed on 19 Mar 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Marschel, Ardin H.
LREP Seidman, Stephanie L.Heller Ehrman White & McAuliffe
CLMN Number of Claims: 44
ECL Exemplary Claim: 1

DRWN 34 Drawing Figure(s); 29 Drawing Page(s)
LN.CNT 2292
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides fast and highly accurate **mass spectrometer** based processes for directly sequencing a target nucleic acid (or fragments generated from the target nucleic acid), which by means of protection, specificity of enzymatic activity, or immobilization, are unilaterally degraded in a stepwise manner via exonuclease digestion and the nucleotides, derivatives or truncated sequences detected by **mass spectrometry**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 21 USPATFULL
AN 2000:132005 USPATFULL
TI 2'-O-aminooxy-modified oligonucleotides
IN Cook, Phillip Dan, Escondido, CA, United States
Manoharan, Muthiah, Carlsbad, CA, United States
Kawasaki, Andrew Mamoru, Oceanside, CA, United States
PA ISIS Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S. corporation)
PI US 6127533 20001003
AI US 1998-16520 19980130 (9)
PRAI US 1997-37143P 19970214 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Crane, L. Eric
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 29 Drawing Figure(s); 29 Drawing Page(s)
LN.CNT 3559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nucleotide compositions containing aminooxy moieties are provided. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the nucleoside moieties of the oligonucleotide is modified to include an aminooxy moiety.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 21 USPATFULL
AN 2000:74089 USPATFULL
TI DNA sequencing by **mass spectrometry** via exonuclease degradation
IN Koster, Hubert, Concord, MA, United States
PA Sequenom, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6074823 20000613
AI US 1996-744590 19961106 (8)
RLI Continuation-in-part of Ser. No. US 1995-388171, filed on 10 Feb 1995, now patented, Pat. No. US 5622824, issued on 22 Apr 1997 which is a continuation of Ser. No. US 1993-34738, filed on 19 Mar 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: LeGuyader, John L.; Assistant Examiner: Larson, Thomas G.
LREP Seidman, Stephanie L.Heller Ehrman White & McAuliffe
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 29 Drawing Page(s)
LN.CNT 1676
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides fast and highly accurate **mass spectrometer** based processes for directly sequencing a target nucleic acid (or fragments generated from the target nucleic acid), which by means of protection, specificity of enzymatic activity, or immobilization, are unilaterally degraded in a stepwise manner via exonuclease digestion and the nucleotides, derivatives or truncated sequences detected by **mass spectrometry**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 21 USPATFULL
AN 2000:21384 USPATFULL
TI Methods and compositions for enhancing sensitivity in the analysis of biological-based assays
IN Ness, Jeffrey Van, Seattle, WA, United States
Tabone, John C., Bothell, WA, United States
Howbert, J. Jeffry, Bellevue, WA, United States
Mulligan, John T., Seattle, WA, United States
PA Rapigene, Inc., Bothell, WA, United States (U.S. corporation)
PI US 6027890 20000222
AI US 1997-898501 19970722 (8)
RLI Continuation-in-part of Ser. No. US 1997-787521, filed on 22 Jan 1997, now abandoned
PRAI US 1996-10436P 19960123 (60)
US 1996-15402P 19960321 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Houtteman, Scott W.
LREP Seed and Berry LLP
CLMN Number of Claims: 72
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 19 Drawing Page(s)
LN.CNT 6333
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are provided for detecting the binding of a first member to a second member of a ligand pair, comprising the steps of (a) combining a set of first tagged members with a biological sample which may contain one or more second members, under conditions, and for a time sufficient to permit binding of a first member to a second member, wherein said **tag** is correlative with a particular first member and detectable by non-fluorescent spectrometry, or potentiometry, (b) separating bound first and second members from unbound members, (c) cleaving the **tag** from the tagged first member, and (d) detecting the **tag** by non-fluorescent spectrometry, or potentiometry, and therefrom detecting the binding of the first member to the second member.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 21 USPATFULL
AN 2000:10008 USPATFULL
TI Synthetic Haemophilus influenzae conjugate vaccine
IN Chong, Pele, Richmond Hill, Canada
Kandil, Ali, Willowdale, Canada
Sia, Charles, Thornhill, Canada
Klein, Michel, Willowdale, Canada
PA Connaught Laboratories Limited, Willowdale, Canada (non-U.S. corporation)
PI US 6018019 20000125
WO 9315205 19930805
AI US 1994-256839 19941003 (8)
WO 1993-CA41 19930203
19941003 PCT 371 date
19941003 PCT 102(e) date

PRAI GB 1992-2219 19920203
DT Utility
FS Granted
EXNAM Primary Examiner: Stucker, Jeffrey
LREP Sim & McBurney
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 28 Drawing Figure(s); 28 Drawing Page(s)
LN.CNT 2070
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides immunogenic synthetic peptides which are useful alone or in PRP-conjugates in vaccines against Hemophilus influenza infection. Modifications are possible within the scope of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 21 USPATFULL
AN 1999:132241 USPATFULL
TI Synthesis of polyribosylribitol phosphate oligosaccharides
IN Chong, Pele, Richmond Hill, Canada
Kandil, Ali, Willowdale, Canada
Sia, Charles, Thornhill, Canada
Klein, Michel, Willowdale, Canada
PA Connaught Laboratories Limited, North York, Canada (non-U.S. corporation)
PI US 5972349 19991026
AI US 1995-475985 19950607 (8)
RLI Continuation of Ser. No. US 256839
PRAI GB 1992-2219 19920302
DT Utility
FS Granted
EXNAM Primary Examiner: Marschel, Ardin H.
LREP Sim & McBurney
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 28 Drawing Figure(s); 28 Drawing Page(s)
LN.CNT 2097
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Polyribosylribitol phosphate oligosaccharides are produced in a multistep process. The compound of the formula: ##STR1## wherein R.sub.1 is a first protecting group and R.sub.2 is a second protecting group, is coupled to a solid polyethylene glycol monomethyl ether (PEG) support. Following removal of the first protecting group, the resulting compound is coupled with a repeating unit for chain elongation of the formula: ##STR2## The protecting group is removed from the phosphorus atom and the steps of removing the first protecting group, coupling with the repeating unit is repeated until the desired number of repeating units in the oligomer has been terminated. The oligomer then is terminated with a chain terminating molecule of the formula: ##STR3## wherein m is an integer and R.sub.3 is a third protecting group. The resulting PEG-bound protected oligomer is a new product and the oligomer may be cleaved from the support and processed to provide a chemically-reactive functional group for binding the polysaccharide oligomer to a carrier molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 16 OF 21 USPATFULL
AN 1999:21984 USPATFULL
TI DNA sequencing by **mass spectrometry** via exonuclease degradation
IN Koster, Hubert, Concord, MA, United States
PA Sequenom, Inc., San Diego, CA, United States (U.S. corporation)

PI US 5872003 19990216
AI US 1995-453499 19950530 (8)
RLI Division of Ser. No. US 1995-388171, filed on 10 Feb 1995, now patented, Pat. No. US 5622824 which is a continuation of Ser. No. US 1993-34738, filed on 19 Mar 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Redding, David A.
LREP Foley, Hoag & Eliot LLP, Arnold, Esq., Beth E.
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1652
AB Methods for determining the sequence of nucleic acids by cleaving the nucleic acid unilaterally from a first end with an exonuclease activity to sequentially release individual nucleotides, identifying each of the sequentially release nucleotides by **mass spectrometry**, and determining the sequence of the nucleic acid from the identified nucleotides are disclosed. The method is amenable to multiplexing for simulataneously determining more than one nuleic acid sequence.

L9 ANSWER 17 OF 21 USPATFULL
AN 1998:159699 USPATFULL
TI DNA sequencing by **mass spectrometry** via exonuclease degradation
IN Koster, Hubert, Concord, MA, United States
PA Sequenon, Inc., San Diego, CA, United States (U.S. corporation)
PI US 5851765 19981222
AI US 1995-454527 19950530 (8)
RLI Division of Ser. No. US 1995-388171, filed on 10 Feb 1995, now patented, Pat. No. US 5622824 which is a continuation of Ser. No. US 1993-34738, filed on 19 Mar 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Horlick, Kenneth R.; Assistant Examiner: Tung, Joyce
LREP Arnold, Beth E.Foley, Hoag&Eliot LLP
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1765
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for determining the sequence of nucleic acids by cleaving the nucleic acid unilaterally from a first end with an exonuclease activity to sequentially release individual nucleotides, identifying each of the sequentially release nucleotides by **mass spectrometry**, and determining the sequence of the nucleic acid from the identified nucleotides are disclosed. The method is amenable to multiplexing for simulataneously determining more than one nuleic acid sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 18 OF 21 USPATFULL
AN 1998:134811 USPATFULL
TI Oligonucleotide sizing using cleavable primers
IN Monforte, Joseph Albert, Berkeley, CA, United States
Becker, Christopher Hank, Menlo Park, CA, United States
Shaler, Thomas Andrew, San Francisco, CA, United States
Pollart, Daniel Joseph, Menlo Park, CA, United States
PA SRI International, Menlo Park, CA, United States (U.S. corporation)
PI US 5830655 19981103
AI US 1996-639363 19960426 (8)
RLI Continuation-in-part of Ser. No. US 1995-445751, filed on 22 May 1995
DT Utility

FS Granted
EXNAM Primary Examiner: Horlick, Kenneth R.; Assistant Examiner: Tung, Joyce
LREP Evans, Susan T., Fabian, Gary R.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 59 Drawing Figure(s); 24 Drawing Page(s)
LN.CNT 3411
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides modified oligonucleotide primers designed to incorporate a cleavable moiety so that a 3' portion of the primer (linked to an extension product) can be released from an upstream 5' portion of the primer. Upon selective cleavage of the cleavable site, primer extension products that contain about five or fewer base pairs of the primer sequence are released, to provide more useful sizing and sequence information per fragment than extension products containing the entire primer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 19 OF 21 USPATFULL
AN 97:120460 USPATFULL
TI Oligonucleotide sizing using immobilized cleavable primers
IN Monforte, Joseph Albert, Berkeley, CA, United States
Becker, Christopher Hank, Menlo Park, CA, United States
Shaler, Thomas Andrew, San Francisco, CA, United States
Pollart, Daniel Joseph, Menlo Park, CA, United States
PA SRI International, Menlo Park, CA, United States (U.S. corporation)
PI US 5700642 19971223
AI US 1995-445751 19950522 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Campbell, Eggerton A.
LREP Evans, Susan T., Fabian, Gary R.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 48 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 2332
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides modified oligonucleotide primers that (i) are designed for attachment to a solid support in a manner that does not block the ability to extend the primer from its 3' end, and (ii) incorporate a clearable moiety so that a 3' portion of the primer (linked to an extension product) can be released from an immobilized 5' portion. Upon selective cleavage of the cleavable site, a large portion of the primer fragment remains affixed to the solid support. This enables the release of primer extension products that contain about five or fewer base pairs of the primer sequence, to provide more useful sizing and sequence information per fragment than extension products containing the entire primer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 20 OF 21 USPATFULL
AN 97:96561 USPATFULL
TI Synthetic Haemophilus influenzae conjugate vaccine
IN Chong, Pele, Richmond Hill, Canada
Kandil, Ali, Willowdale, Canada
Sia, Charles, Thornhill, Canada
Klein, Michel, Willowdale, Canada
PA Connaught Laboratories Limited, Willowdale, Canada (non-U.S. corporation)
PI US 5679352 19971021
AI US 1995-475989 19950607 (8)
RLI Continuation of Ser. No. US 1994-256839, filed on 3 Oct 1994

PRAI GB 1992-2219 19920302
DT Utility
FS Granted
EXNAM Primary Examiner: Fleisher, Mindy; Assistant Examiner: Degen, Nancy J.
LREP Sim & McBurney
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 28 Drawing Figure(s); 28 Drawing Page(s)
LN.CNT 1882
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Synthetic peptides have an amino acid sequence corresponding to at least one antigenic determinant of at least one protein, usually a structural protein, particularly the P1, P2 and P6 protein, of Haemophilus influenzae (Hi), particularly type b, and are used as is, in chimeric T-B form, in lipidated form, linked to a carrier molecule, particularly a synthetic PRP molecule and/or polymerized to form molecular aggregates, in vaccines against Hi.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 21 OF 21 USPATFULL
AN 97:33619 USPATFULL
TI DNA sequencing by **mass spectrometry** via exonuclease degradation
IN K oster, Hubert, Concord, MA, United States
PA Sequenom, Inc., Boston, MA, United States (U.S. corporation)
PI US 5622824 19970422
AI US 1995-388171 19950210 (8)
RLI Continuation of Ser. No. US 1993-34738, filed on 19 Mar 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Fleisher, Mindy; Assistant Examiner: Wai, Thanda
LREP Lahive & Cockfield, Arnold, Esq., Beth E., DeConti, Jr., Giulio A.
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1719
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for determining the sequence of nucleic acids by cleaving the nueleic acid unilaterally from a first end with an exonuclease activity to sequentially release individual nucleotides, identifying each of the sequentially release nucleotides by **mass spectrometry** , and determining the sequence of the nueleic acid from the identified nucleotides are disclosed. The method is amenable to multiplexing for simultaneously determining more than one nucleic acid sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.